Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion

Clare Keddy, Tanaya Neff, Jianya Huan, Joshua P. Nickerson, Catherine Z. Beach, Yassmine Akkari, Jianling Ji, Stephen Moore, Kellie J. Nazemi, Christopher L. Corless, Carol Beadling, Randy Woltjer, Yoon Jae Cho, Matthew D. Wood, Monika A. Davare

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Chromosomal rearrangements of the NTRK genes generate kinase fusions that are targetable oncogenic drivers in diverse adult and pediatric malignancies. Despite robust clinical response to targeted NTRK inhibition, the emergence of therapeutic resistance poses a formidable clinical challenge. Here we report the characterization of an ETV6- NTRK3 fusion-driven pediatric glioma that progressed through NTRK-targeted treatments with entrectinib and selitrectinib. Genetic analysis of multifocal recurrent/resistant lesions identified a previously uncharacterized NTRK3 p.G623A and a known p.G623E resistance mutation, in addition to other alterations of potential pathogenic impact. Functional studies using heterologous reconstitution model systems and patient-derived tumor cell lines establish that NTRK3G623A and NTRK3G623E mutated kinases exhibit reduced sensitivity to entrectinib and selitrectinib, as well as other NTRK inhibitors tested herein. In summary, this genetic analysis of multifocal recurrent/resistant glioma driven by ETV6-NTRK3 fusion captured a cross section of resistance-associated alterations that, based on in vitro analysis, likely contributed to resistance to targeted therapy and disease progression.

Original languageEnglish (US)
Article numbera006109
JournalCold Spring Harbor Molecular Case Studies
Issue number5
StatePublished - Dec 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion'. Together they form a unique fingerprint.

Cite this